120241-79-4
Chemical Structure
3-TYP
- CAS No.: 120241-79-4
- Formula:C7H6N4
- Molecular Weight:146.15
IUPAC Name: 3-(1H-1,2,3-triazol-5-yl)pyridine
InChIKey: VYXFEFOIYPNBFK-UHFFFAOYSA-N
SMILES: C1(C2=CN=NN2)=CC=CN=C1
Biological Activity: 3-TYP is an inhibitor of SIRT3 (IC50of 38 μM) and an inhibitor of Methionine Adenosyltransferase (MAT) 2 and Indoleamine 2,3-Dioxygenase (IDO). There may be many off-target sites for 3-TYP that need to be examined, such as NAD-dependent enzymes, including dehydrogenases[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
3-TYP | 99.90% | 3-TYP is an inhibitor of SIRT3 (IC50of 38 μM) and an inhibitor of Methionine Adenosyltransferase (MAT) 2 and Indoleamine 2,3-Dioxygenase (IDO). There may be many off-target sites for 3-TYP that need to be examined, such as NAD-dependent enzymes, including dehydrogenases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-TYP (Standard) | 3-TYP (Standard) is the analytical standard of 3-TYP (HY-108331). This product is intended for research and analytical applications. 3-TYP is an inhibitor of SIRT3 (IC50of 38 μM) and an inhibitor of Methionine Adenosyltransferase (MAT) 2 and Indoleamine 2,3-Dioxygenase (IDO). There may be many off-target sites for 3-TYP that need to be examined, such as NAD-dependent enzymes, including dehydrogenases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Pi H, et al. SIRT3-SOD2-mROS-dependent autophagy in cadmium-induced hepatotoxicity and salvage by melatonin. Autophagy. 2015;11(7):1037-51. [Content Brief]
- [2]. Zhai M, et al. Melatonin ameliorates myocardial ischemia reperfusion injury through SIRT3-dependent regulation of oxidative stress and apoptosis. J Pineal Res. 2017 Sep;63(2). [Content Brief]
- [3]. Galli U, et al. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2. Eur J Med Chem. 2012 Sep;55:58-66. [Content Brief]
Keywords